Document:

EX-10.13

 Exhibit 10.13 

CONSULTING AGREEMENT 

THIS AGREEMENT is made and entered into as of March 11, 2014 ( “Effective Date”) by and between Vyrix Pharmaceuticals,
Inc., a Delaware corporation (the “Company”), and Dr. Vaughan L. Clift, an individual (“Consultant”). The Company and the Consultant are each a “Party” and collectively the
“Parties”. 
 The Company and Consultant hereby agree as follows: 

1. Services. The Company hereby engages Consultant to provide to the Company, and Consultant agrees to provide to the Company under the terms and
conditions of this Agreement, the services as mutually agreed upon by the Company and Consultant from time to time (hereinafter the “Services”). 

2. Consideration. Subject to approval by the Company’s Board of Directors, and as consideration for Consultant’s rendering the Services, the
Company shall grant Consultant options to purchase 150,000 shares of the Company’s Common Stock (the “Options”). The exercise price of the Options will be equal to the fair market value per share on the date the Options are
granted. The Options will be subject to the terms and conditions of the Company’s 2013 Stock Option and Grant Plan and the definitive agreement evidencing the Options. The Options will vest according to the following schedule: 25% of the shares
underlying the Options shall vest upon grant and the remaining shares shall vest in three equal annual installments commencing on the first anniversary of the grant date, provided that as of each such date Consultant is providing Services to the
Company. 
 3. Expenses. The Company shall reimburse Consultant for reasonable and necessary out-of-pocket expenses incurred by Consultant in the
performance of the Services, provided such out-of-pocket expenses are approved in advance by an officer of the Company and further are supported by reasonable documentation. 

4. Cancellation of Services. Either Party may at any time terminate the performance of all or any portion of the Services to be provided hereunder and
may terminate this Agreement upon thirty (30) days prior written notice to the non-terminating Party stating its intention to terminate and, if applicable, specifying the portion of the Services to be terminated. 

5. Term of Agreement; Termination. The term of this Agreement and Consultant’s Services hereunder shall commence as of the Effective Date of this
Agreement and shall continue until terminated as a result of the death, physical incapacity or mental incompetence of Consultant, which shall result in automatic termination, or pursuant to Section 4. Except as otherwise explicitly provided
herein, the provisions of Sections 5 and 6 shall survive the termination or expiration of this Agreement for any reason. 
 6. Miscellaneous. This
Agreement together with all exhibits hereto, contains the entire understanding of the Parties with respect to the matters contained herein, and supersedes all proposals and agreements, written or oral, and all other communications between the
Parties relating to the subject matter of this Agreement. Neither this Agreement nor any right or obligation hereunder or interest herein may be assigned or transferred by Consultant without the express written consent of the Company. The Company
may assign this Agreement to its affiliates, successors and assigns. Consultant expressly consents to be bound by the provisions of this Agreement for the benefit of the Company or any parent, subsidiary or affiliate to whom Consultant’s
Services may be transferred without the necessity that this Agreement be resigned at the time of such transfer. This Agreement shall be governed by and construed in accordance with the laws of State of Delaware without regard to its conflict of laws
rules. This Agreement may not be modified or amended except in writing signed or executed by Consultant and the Company. In case any provisions (or portions thereof) contained in this Agreement will, for any reason,

 
be held invalid, illegal or unenforceable in any respect, such invalidity, illegality or unenforceability will not affect the other provisions of this Agreement, and this Agreement will be
construed as if such invalid, illegal or unenforceable provision had never been contained herein. If, moreover, any one or more of the provisions contained in this Agreement shall for any reason be held to be excessively broad as to duration,
geographical scope, activity or subject, it will be construed by limiting and reducing it, so as to be enforceable to the extent compatible with the applicable law as it will then appear. 

[Remainder of Page Intentionally Left Blank] 

 IN WITNESS WHEREOF, the Parties have caused this Agreement to be duly executed as of the date
last below written. 
  

							
	DR. VAUGHAN L. CLIFT	 	 	 	VYRIX PHARMACEUTICALS, INC.
				
	 /s/ Vaughan Clift
	 		 	By:	 	 /s/ Jarrett Disbrow

	 Name (Print): Vaughan Clift
	 		 	Name (Print) Jarrett Disbrow
	 Address: 10260 Longview Dr.
	 		 	Title: President and CEO
	 Lone Tree, CO 80124
	 		 		 	        Date: 3/12/2014
				
	 Date: 3/12/2014EX-10.1

 Exhibit 10.1 

CONSENT 
 May 1, 2014 

NeoPhotonics Corporation 
 2911 Zanker Road 

San Jose, California 95134 
 Attention: Ray Wallin 

 

	 	Re:	Consent (“Consent”) in connection with that certain Revolving Credit and Term Loan Agreement dated as of March 21, 2013 (as amended, restated or otherwise modified from time to time, the “Credit
Agreement”), by and among NeoPhotonics Corporation (“Borrower”), the financial institutions from time to time parties thereto (collectively, the “Lenders”) and Comerica Bank, as administrative agent for the Lenders (in such
capacity, the “Agent”). 

 Ladies and Gentlemen: 

Reference is made to the Credit Agreement. Except as specifically defined to the contrary in this Consent, capitalized terms used herein shall
have the meanings given them in the Credit Agreement. 
 1.    Borrower has requested that Agent and the Lenders consent
to an extension of the due date for the financial statements of Borrower required under Section 7.1(a) of the Credit Agreement for the Fiscal Year ended December 31, 2013. Subject to the terms and conditions of this Consent, Agent and the
Lenders hereby consent to the extension until May 31, 2014 (or such later date as may be approved by the Majority Lenders) of the due date for the financial statements of Borrower for the Fiscal Year ended December 31, 2013. 

2.    Borrower has requested that Agent and the Lenders consent to an extension of the due date for the financial
statements of Borrower required under Section 7.1(b) of the Credit Agreement for the fiscal quarter ended March 31, 2014. Subject to the terms and conditions of this Consent, Agent and the Lenders hereby consent to the extension until
June 15, 2014 (or such later date as may be approved by the Majority Lenders) of the due date for the financial statements of Borrower for the fiscal quarter ended March 31, 2014. 

3.    Borrower has also requested that Agent and the Lenders consent to an extension of (a) the due date for the
Securities and Exchange Commission report of Borrower on Form 10- K for the Fiscal Year ended December 31, 2013 required under Section 7.1(c)(i) of the Credit Agreement and (b) the due date for the Securities and Exchange Commission
report of Borrower on Form 10-Q for the fiscal quarter ended March 31, 2014 required under Section 7.1(c)(ii) of the Credit Agreement. Subject to the terms and conditions of this Consent, Agent and the Lenders hereby consent to the
extension until May 31, 2014 (or such later date as may be approved by the Majority Lenders) of the due date for the report on Form 10-K for the Fiscal Year ended December 31, 2013 and the extension until June 15, 2014 (or such later
date as may be approved by the Majority Lenders) of the due date for the report on Form 10-Q for the fiscal quarter ended March 31, 2014. 

 4.    This Consent shall become effective (according to the terms hereof) on
the date that Agent shall have received fully executed signature pages of this Consent, in each case duly executed and delivered by Agent, Borrower and the requisite Lenders. Borrower shall deliver original executed signature pages to this Consent
promptly after the date hereof. 
 5.    Borrower hereby represents and warrants that, after giving effect to this
Consent, (a) the representations and warranties set forth in Section 6 of the Credit Agreement are true and correct in all material respects on and as of the date hereof (other than any such representation or warranty which expressly
speaks only as of a different date); and (b) as of the date hereof, no Default or Event of Default has occurred and is continuing. 

6.    Except as expressly set forth herein, this Consent shall not be deemed to amend or alter in any respect the terms and
conditions of the Credit Agreement (including without limitation all conditions and requirements for Advances and any financial covenants) or any of the other Loan Documents, or to constitute a waiver or release by any of the Lenders or Agent of any
right, remedy, Collateral, Default or Event of Default under the Credit Agreement or any of the other Loan Documents, except to the extent specifically set forth herein. Furthermore, this Consent shall not affect in any manner whatsoever any rights
or remedies of the Lenders or Agent with respect to any other non-compliance by Borrower or any other Credit Party with the Credit Agreement or the other Loan Documents, whether in the nature of a Default or Event of Default, and whether now in
existence or subsequently arising, and shall not apply to any other transaction 
 7.    This Consent shall be a contract
made under and governed by the internal laws of the State of California (without giving effect to principles of conflict of laws), and may be executed in counterpart, in accordance with Section 13.9 of the Credit Agreement. 

[Remainder of Page Intentionally Left Blank] 

 By signing and returning a counterpart of this Consent to Agent, Borrower acknowledges its
acceptance of the terms of this Consent. This Consent shall not become effective unless and until countersigned by Borrower and returned to Agent. 
  

			
	Very truly yours,
	
	COMERICA BANK, as Agent
		
	By:	 	 /s/ Robert Shutt

	Name:	 	Robert Shutt
	Title:	 	Senior Vice President

 Acknowledged and Accepted as of the date and year first above written: 

 

			
	NEOPHOTONICS CORPORATION
		
	By:	 	 /s/ Clyde R. Wallin

	Name:	 	Clyde R. Wallin
	Title:	 	Senior Vice President and Chief Financial Officer

 Acknowledged and Accepted as of the date and year first above written: 

 

			
	 COMERICA BANK, as a Lender, Issuing Lender

and Swing Line Lender

		
	By:	 	 /s/ Robert Shutt

	Name:	 	Robert Shutt
	Title:	 	Senior Vice President
	
	 EAST WEST BANK,
 as a
Lender

		
	By:	 	 /s/ Nader Maghsoudnia

	Name:	 	Nader Maghsoudnia
	Title:	 	Director

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00230-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00230-of-00352.parquet"}]]